Pregnancy safety study of the VLA1553 vaccine
Treatments studied
Part of Infections clinical trials.
This study follows pregnant women who received the VLA1553 vaccine (for chikungunya) to see how it affects them and their babies. It compares them to pregnant women who received a different vaccine approved during pregnancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant at the time you join the study.
- You received the VLA1553 vaccine while pregnant or within 30 days before your last period started (for the vaccinated group).
- Or you did NOT receive the VLA1553 vaccine, but you did receive another vaccine approved for use during pregnancy (for the control group).
- You understand the study and agree to follow its rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the VLA1553 vaccine prevents chikungunya disease in parts of Brazil where the vaccine is being offered as part of a pilot program. If you live in one of those areas and have had symptoms that might be chikungunya, this study will use your health records and blood tests to check how effective the vaccine is.
This study tests an experimental vaccine designed to protect against chikungunya, a mosquito-borne virus that causes fever and joint pain. The trial will evaluate the vaccine's safety and immune response in healthy adults.
This trial tests a new treatment (PC-CHIK-V) for newborns whose mothers had chikungunya around the time of birth. The goal is to see if the treatment can prevent or reduce the infection in babies. Babies who are not treated will also be followed for comparison.
This study looks at how well the chikungunya vaccine works in real life, how safe it is, and how the body's immune system responds. It is for adults who are eligible for the vaccine according to French health guidelines.
This study tests how well the chikungunya vaccine (IXCHIQ) triggers an immune response in people aged 12 to 59. It is a phase 2 trial to see if the vaccine produces a good antibody response.
This trial tests an experimental chikungunya vaccine (made from a virus-like particle) to see if it prevents the disease. It is for healthy teens and adults who have not had chikungunya before.
Hear when a new Chikungunya Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.